Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
-5.12%
$9.94
0% positive prob.
5-Day Prediction
-9.92%
$9.44
0% positive prob.
20-Day Prediction
-8.95%
$9.54
0% positive prob.
| Quarter | Signal | 1D Return | 5D Return | 20D Return | Confidence | Actual 5D |
|---|---|---|---|---|---|---|
| Q3 2026 | SELL | -5.12% | -9.92% | -8.95% | 100.0% | Pending |
| Q3 2026 | SELL | -5.12% | -9.92% | -8.95% | 100.0% | Pending |
| Q2 2026 | SELL | -5.28% | -9.93% | -8.96% | 100.0% | +4.69% |
| Q1 2026 | SELL | +0.00% | +0.00% | +0.00% | 100.0% | -12.62% |
| Q4 2025 | SELL | -5.77% | -9.82% | -9.34% | 100.0% | -7.91% |
SEC 8-K filings with transcript text
Nov 12, 2026 · 100% conf.
1D
-5.12%
$11.68
Act: +1.17%
5D
-9.92%
$11.09
20D
-8.95%
$11.21
2 ntla-ex99_1.htm
Readying Lonvo-z forPatients with HAE November 12, 2026 Exhibit 99.1
This presentation contains “forward-looking statements” of Intellia Therapeutics, Inc. (“Intellia”, “we” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements about Intellia’s beliefs and expectations regarding: our ability to successfully develop and commercialize lonvoguran ziclumeran (“lonvo-z”), previously referred to as NTLA-2002, for the treatment of hereditary angioedema (“HAE”), including our ability to obtain approval for the biologics license application for lonvo-z for the treatment of HAE and successfully launch lonvo-z for the treatment of HAE; the potential commercial opportunities for lonvo-z, including the value and market potential for lonvo-z, and the potential to completely redefine HAE treatment; and the potential of lonvo-z to reduce burden and generate value for patients, HCPs, payers and the overall healthcare system. Any forward-looking statements in this presentation are based on management’s current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to our ability to successfully develop and commercialize lonvo-z or any of our other product candidates; risks related to Intellia’s ability to protect and maintain its intellectual property position; risks related to Intellia’s relationship with third parties, including our contract manufacturers, licensors and licensees; risks related to the ability of our licensors to protect and maintain their intellectual property position; uncertainties related to the authorization, initiation and conduct of preclinical and clinical studies and other development requirements for our product candidates, including uncertainties related to regulatory approvals to conduct clinical trials; risks related to the results of preclinical studies or clinical studies not being predictive of future results in connection with future studies; the risk that clinical trial results will not be positive; risks related to the development and advancement of CRISPR gene editing and other core technologies technologies for pipeline expansion and collaborations; risks related to Intellia’s future financial condition and our ability to fund our operations; risks related to Intellia’s collaborations with Regeneron Pharmaceuticals, Inc. or our other collaborations not continuing or not being successful; and risks related to Intellia's ability to execute its strategic plans, including completing pivotal clinical trials and commercial launch of its product candidates. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Intellia’s most recent Annual Report of Form 10-K and Quarterly Report on Form 10-Q as well as discussions of potential risks, uncertainties, and other important factors in Intellia’s other filings with the Securities and Exchange Commission. All information in this presentation is as of the date on its cover page, and Intellia undertakes no duty to update this information unless required by law. Intellia Therapeutics’ Legal Disclaimer
Today’s Speakers and Topics Introduction and Overview Dr. John Leonard President and Chief Executive Officer Intellia Therapeutics HAE Management in the U.S. Dr. Marc Riedl Prof. of Medicine, Clinical Director of the U.S. Hereditary Angioedema Association (HAEA) Angioedema Center University of California San Diego; HAELO principal investigator Lonvo-z Clinical Data Dr. Jing L. Marantz Executive Vice President and Chief Medical Officer Intellia Therapeutics Lonvo-z Patient Perspectives Dr. Danny Cohn Internist, Department of Vascular Medicine, Amsterdam Cardiovascular Sciences Amsterdam University Medical Center; HAELO principal investigator Lonvo-z Commercial Readiness Maria Natale Senior Vice President, Commercial Intellia Therapeutics 1 2 3 4 5 AGENDA Q&A SESSION HAE: hereditary angioedema.
Introduction & Overview Dr. John Leonard President & Chief Executive Officer Intellia Therapeutics
Intellia is Leading a New Era of Medicine CRISPR: clustered regularly interspaced short palindromic repeats; Cas9: CRISPR-associated protein 9; ATTR-CM: ATTR amyloidosis cardiomyopathy; ATTRv-PN: hereditary ATTR amyloidosis polyneuropathy; KLKB1: kallikrein B1. Working diligently to bring the first-ever in vivo CRISPR-based therapies to patients living with severe diseases 2 Additional Phase 3 Trials ongoing in transthyretin amyloidosis (ATTR-CM & PN) Pat
Nov 5, 2026 · 100% conf.
1D
-5.12%
$11.68
Act: +1.17%
5D
-9.92%
$11.09
20D
-8.95%
$11.21
2 ntla-ex99_1.htm
Exhibit 99.1
Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates
- On track to complete lonvo-z commercial readiness efforts in advance of March 10, 2027 PDUFA date
- New lonvo-z patient perspectives and Phase 1/2 durability data to be included in investor webcast and multiple presentations next week at ACAAI 2026
- Completed enrollment in MAGNITUDE-2 Phase 3 clinical trial in ATTRv-PN; advanced enrollment in MAGNITUDE in ATTR-CM
- Existing cash resources expected to fund operations at least into 2028 and well beyond lonvo-z’s anticipated commercial launch, with recent term loan facility providing additional financial flexibility
CAMBRIDGE, Mass., November 5, 2026 – Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today reported business updates and financial results for the third quarter ended September 30, 2026.
“This is a defining period for Intellia as we advance our late-stage pipeline and prepare for a transformative year ahead,” said John Leonard, M.D., Intellia President and Chief Executive Officer. “We have assembled the teams and capabilities needed to support a successful launch in HAE while also continuing to advance nex-z’s Phase 3 clinical trials and our pipeline expansion efforts. Looking to 2027, we are working toward a historic milestone: the potential approval of lonvo-z as the world’s first in vivo CRISPR-based therapy. As a one-time treatment, we believe it could transform the HAE treatment paradigm while also delivering significant value to patients, physicians, payers and the overall healthcare system.”
Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)
Designed as a one-time treatment that is administered in an outpatient setting, lonvo-z is an in vivo CRISPR gene editing candidate that is intended to inactivate the kallikrein B1 (KLKB1) gene to permanently lower kallikrein and bradykinin levels and to eliminate HAE attacks and the need for lifelong treatment.
• In September, the U.S. Food and Drug Administration (FDA) accepted the Biologics License Application (BLA) for lonvo-z and granted the BLA Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date of March 10, 2027. Additionally, FDA advised that it is not
Page 1 of 5
intelliatx.com
currently planning to hold an advisory committee to discuss the application. If approved, lonvo-z would be the world’s first in vivo CRISPR-based therapy and the only one-time treatment for HAE.
• Intellia significantly advanced its launch readiness in recent months, completing the deployment of its field organization and deepening its engagement with HAE treatment centers and payers in preparation for a planned commercial launch in the first quarter of 2027.
Nexiguran Ziclumeran (Nex-z) for Transthyretin (ATTR) Amyloidosis
Nex-z is an in vivo CRISPR-based therapeutic candidate designed to inactivate the TTR gene in the liver, thereby preventing the production of transthyretin (TTR) protein. Nex-z offers the possibility of halting and reversing disease by driving a rapid, deep, consistent and potentially lifelong reduction in TTR protein after a one-time treatment. Intellia leads the development and commercialization of nex-z in collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron).
• Intellia has made significant progress advancing enrollment in its MAGNITUDE Phase 3 clinical trial in ATTR amyloidosis with cardiomyopathy (ATTR-CM).
• During the third quarter, the company completed enrollment in its MAGNITUDE-2 Phase 3 clinical trial in hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN), exceeding its targeted randomization of 60 patients.
• During the third quarter, Intellia began providing investigators with human leukocyte antigen (HLA) genotyping results for patients enrolled or entering screening in the ongoing nex-z Phase 3 trials.
Other Recent Updates
• In September, Intellia entered into a non-dilutive senior secured term loan facility with OrbiMed, a leading global healthcare investment firm, for up to $400 million. The transaction provides Intellia with greater financial and operational flexibility as it advances toward several key milestones, including the planned U.S. approval and commercial launch of lonvo-z in HAE.
• In October, the company announced the appointment of Jing L. Marantz, M.D., Ph.D., as Executive Vice President and Chief Medical Officer. Dr. Marantz is an accomplished drug development leader with more than 25 years of experience in the biopharmaceutical industry that includes the successful advancement of several now-approved rare disease therapies. In this role, she is leading the company’s translational, development, regulatory and medical affairs functions.
Upcoming Events
The company will participate in the following upcoming events:
Aug 6, 2026 · 100% conf.
1D
-5.28%
$10.70
Act: +5.66%
5D
-9.93%
$10.18
Act: +4.69%
20D
-8.96%
$10.29
2 ntla-ex99_1.htm
Exhibit 99.1
Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
- Positive Phase 3 HAELO clinical data for lonvo-z in HAE presented at EAACI and published in New England Journal of Medicine
- Anticipate FDA acceptance of BLA for lonvo-z in second half of 2026 and U.S. launch in first half of 2027
- Enrollment successfully reinitiated in nex-z Phase 3 clinical trials; MAGNITUDE-2 enrollment in ATTRv-PN expected to be completed in second half of 2026
- New genomic insights enhance understanding of nex-z’s profile and potential to deliver clinically meaningful outcomes for patients
- Ended second quarter with approximately $628 million in cash, cash equivalents and marketable securities; expected to fund operations at least into 2028
CAMBRIDGE, Mass., August 6, 2026 – Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today reported business updates and financial results for the second quarter ended June 30, 2026.
“The second quarter was a momentous period for Intellia highlighted by the positive Phase 3 HAELO clinical trial results we reported for lonvo-z in hereditary angioedema,” said John Leonard, M.D., Intellia President and Chief Executive Officer. “These data serve as strong validation for in vivo gene editing and lonvo-z’s potential to transform the treatment paradigm for patients who are burdened by this disease.”
“We also resumed enrollment in our Phase 3 clinical trials in ATTR during the second quarter and gained important new genomic insights that enhance our understanding of nex-z’s safety profile and its potential to deliver clinically meaningful outcomes for patients. Underpinned by a recent capital raise that strengthened our balance sheet, we are well positioned to deliver on our research, regulatory, clinical and commercial objectives,” Dr. Leonard concluded.
Page 1 of 6
intelliatx.com
Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)
Designed as a one-time treatment that is administered in an outpatient setting, lonvo-z is an in vivo CRISPR gene editing candidate that is intended to inactivate the kallikrein B1 (KLKB1) gene to permanently lower kallikrein and bradykinin levels and to eliminate HAE attacks.
• In April, Intellia announced positive topline results from the global Phase 3 HAELO clinical trial of lonvo-z in HAE. In June, additional data were reported in a late-breaking oral session at the European Academy of Allergy & Clinical Immunology Annual Congress 2026 and in a manuscript published in the New England Journal of Medicine. Highlights included:
- The trial met its primary endpoint. For the six-month efficacy evaluation period (weeks 5 to 28), a one-time infusion of lonvo-z reduced attacks by 87% versus placebo, with a mean monthly attack rate of 0.26 in the lonvo-z arm compared with 2.10 in the placebo arm (p<0.0001).
- The trial met all of its key secondary endpoints with statistical significance (p<0.0001). These included:
▪ 62% of patients were entirely attack free and therapy free in the lonvo-z arm for the six-month efficacy evaluation period, compared with 11% of patients in the placebo arm;
▪ The mean monthly rate of attacks requiring on-demand treatment was 0.19 in the lonvo-z arm for the six-month efficacy evaluation period, compared with 1.79 in the placebo arm;
▪ The mean monthly rate of moderate/severe attacks was 0.11 in the lonvo-z arm for the six-month efficacy evaluation period, compared with 1.23 in the placebo arm; and
▪ The change in Angioedema Quality of Life (AE-QoL) total score was -23.51 in the lonvo-z arm from baseline to week 28, compared with -6.47 in the placebo arm.
- All patients in the lonvo-z arm experienced attack-rate reductions from baseline compared with weeks 5 to 28.
- Attack-rate reductions were observed for all evaluated subgroups.
- All patients who received lonvo-z at baseline or in crossover after week 28 remained free from long-term prophylaxis therapy as of the February 10, 2026 data cutoff.
- Favorable safety and tolerability data were observed for lonvo-z. The most common treatment emergent adverse events (TEAEs) were infusion-related reactions, headache, fatigue, back pain, and upper respiratory tract infection. All TEAEs reported were mild or moderate (Grade 1 or Grade 2), and there were no serious adverse events observed in the lonvo-z arm.
• During the second quarter, the company launched www.HAEreframed.com. The campaign aims to raise awareness of the significant burden of HAE and patients’ top concerns, including the
Page 2 of 6
intelliatx.com
mental toll of the disease and the challenges of taking and maintaining access to chronic treatment.
• Intellia significantly advanced its launch readiness activities in recent months, including finalizing its field medical, reimburseme
This page provides Intellia Therapeutics Inc. (NTLA) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on NTLA's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.